Literature DB >> 18165522

Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania.

Mohammad A Al-Wabel1, Willy K Tonui, Liwang Cui, Samuel K Martin, Richard G Titus.   

Abstract

Leishmania major culture-derived, soluble, exogenous antigens have been shown to be a source of vaccine targets for the parasite. We have previously reported that L. major culture-derived, soluble, exogenous antigens can immunize BALB/c mice against challenge with L. major. However, the molecule(s) involved in this protection was not known. We describe the potential of one component of soluble exogenous antigens (recombinant nucleoside hydrolase) to vaccinate mice against challenge with L. major. We found that recombinant nucleoside hydrolase vaccinated BALB/c mice against a subsequent challenge with L. major. Protection was manifested by a significant decrease in lesion size (as much as a 30-fold reduction) and parasite burden (as much as a 71-fold reduction). Protection was achieved whether recombinant nucleoside hydrolase was administered to mice in the presence or absence of adjuvant (interleukin-12). Finally, protection was accompanied by an increase in interferon-gamma production but a decrease in interleukin-10 production by vaccinated animals in response to challenge with L. major.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18165522

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

2.  CCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 and NF-kappa B.

Authors:  Fabio Jimenez; Marlon P Quinones; Hernan G Martinez; Carlos A Estrada; Kassandra Clark; Edgar Garavito; Jessica Ibarra; Peter C Melby; Seema S Ahuja
Journal:  J Immunol       Date:  2010-04-19       Impact factor: 5.422

3.  Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.

Authors:  Dirlei Nico; Carla Claser; Gulnara P Borja-Cabrera; Luiz R Travassos; Marcos Palatnik; Irene da Silva Soares; Mauricio Martins Rodrigues; Clarisa B Palatnik-de-Sousa
Journal:  PLoS Negl Trop Dis       Date:  2010-11-09

4.  Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.

Authors:  Elissa M Hudspeth; Qian Wang; Christopher A Seid; Molly Hammond; Junfei Wei; Zhuyun Liu; Bin Zhan; Jeroen Pollet; Michael J Heffernan; C Patrick McAtee; David A Engler; Risë K Matsunami; Ulrich Strych; Oluwatoyin A Asojo; Peter J Hotez; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

5.  Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infection.

Authors:  Herbert Leonel de Matos Guedes; Beatriz Lilian da Silva Costa; Suzana Passos Chaves; Daniel Cláudio de Oliveira Gomes; Joshua Daniel Nosanchuk; Salvatore Giovanni De Simone; Bartira Rossi-Bergmann
Journal:  Parasit Vectors       Date:  2014-09-19       Impact factor: 3.876

Review 6.  Vaccines to prevent leishmaniasis.

Authors:  Rajiv Kumar; Christian Engwerda
Journal:  Clin Transl Immunology       Date:  2014-03-14

7.  F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.

Authors:  Eugenia Carrillo; Laura Fernandez; Ana Victoria Ibarra-Meneses; Micheli L B Santos; Dirlei Nico; Paula M de Luca; Cristiane Bani Correa; Roque Pacheco de Almeida; Javier Moreno; Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2017-07-12       Impact factor: 7.561

8.  Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.

Authors:  Micheli Luize Barbosa Santos; Dirlei Nico; Fabrícia Alvisi de Oliveira; Aline Silva Barreto; Iam Palatnik-de-Sousa; Eugenia Carrillo; Javier Moreno; Paula Mello de Luca; Alexandre Morrot; Daniela Santoro Rosa; Marcos Palatnik; Cristiane Bani-Corrêa; Roque Pacheco de Almeida; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2017-03-07       Impact factor: 7.561

9.  Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains.

Authors:  Dirlei Nico; Daniele Crespo Gomes; Marcus Vinícius Alves-Silva; Elisangela Oliveira Freitas; Alexandre Morrot; Diana Bahia; Marcos Palatnik; Mauricio M Rodrigues; Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2014-05-01       Impact factor: 7.561

10.  Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.

Authors:  Dirlei Nico; Daniele Crespo Gomes; Iam Palatnik-de-Sousa; Alexandre Morrot; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2014-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.